Diabetic Retinopathy News and Research RSS Feed - Diabetic Retinopathy News and Research

In the initial stages, people with diabetic retinopathy may not notice their vision changing. Diabetics sometimes experience rapid changes in blood sugar that can temporarily cause blurry vision even when retinopathy is not present. If a person notices a few specks or spots floating in his visual field, this may mean he has developed proliferative diabetic retinopathy, the growth of abnormal new blood vessels on the retina and optic nerve. High blood sugar levels have been linked in studies to retinal blood vessel abnormalities. Blurred vision may occur when the macula--the small area at the center of the retina--swells as it fills with fluid that has leaked from retinal blood vessels. Because damage to the eye often develops slowly, early detection of diabetes and control of blood sugar through diet and medications can make a crucial difference in saving vision.

Effective diabetic retinopathy treatments include laser photocoagulation for early to moderate stages and a microsurgery called vitrectomy for repair of eyes with extensive damage. Injectable and oral medications that act on abnormal blood vessels to control diabetic retinopathy before vision loss occurs are now in development. Early detection would be key to the effectiveness of these treatments, also.
Macular ischaemia, retinal thinning linked to reduced visual function in diabetic retinopathy

Macular ischaemia, retinal thinning linked to reduced visual function in diabetic retinopathy

Macular ischemia and retinal thinning are associated with reduced visual function in patients with diabetic retinopathy, research suggests. [More]
Penn Medicine launches CAROT to build novel therapies for retinal and ocular disorders

Penn Medicine launches CAROT to build novel therapies for retinal and ocular disorders

The Perelman School of Medicine at the University of Pennsylvania has launched the Penn Center for Advanced Retinal and Ocular Therapeutics (CAROT) to build on its previous success developing novel therapies for the personalized diagnosis and treatment of retinal and ocular disorders. [More]
KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

KalVista begins Phase I trial of novel plasma kallikrein inhibitor for treatment of DME

KalVista Pharmaceuticals, an ophthalmology company with a focus on diabetic macular edema (DME), today announces that it has begun a Phase I, First in Human, trial of its novel plasma kallikrein inhibitor, KVD001, for the treatment of DME. [More]
FGF proteins play broad roles in wound healing

FGF proteins play broad roles in wound healing

Mice missing two important proteins of the vascular system develop normally and appear healthy in adulthood, as long as they don't become injured. If they do, their wounds don't heal properly, a new study shows. [More]
European Commission approves EYLEA Injection for treatment of visual impairment due to DME

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron Pharmaceuticals, Inc. today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema. [More]
Inadequate management common in young-onset Type 2 diabetes

Inadequate management common in young-onset Type 2 diabetes

Patients with young-onset Type 2 diabetes have worse metabolic control than those with late-onset disease, but they are less likely to receive organ-protective drugs, show data from the Joint Asia Diabetes Evaluation cohort. [More]
Complete analysis of retinopathy screening devices in the US market

Complete analysis of retinopathy screening devices in the US market

Reportbuyer.com has added a new market research report: U.S. Market and Survey for Retinopathy Screening Devices [More]
Salt poses cardiovascular risk in diabetic patients

Salt poses cardiovascular risk in diabetic patients

A diet high in salt increases the risk of cardiovascular disease in patients with Type 2 diabetes, show data from the Japan Diabetes Complications Study. [More]
Regeneron announces FDA approval of EYLEA Injection for DME treatment

Regeneron announces FDA approval of EYLEA Injection for DME treatment

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). [More]
FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

FDA approves EYLEA Injection for treatment of Diabetic Macular Edema

Regeneron Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration has approved EYLEA (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). [More]
Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Phase 3 VIVID-DME trial of EYLEA Injection for treatment of DME shows improvement in visual acuity

Regeneron Pharmaceuticals, Inc. today announced that in the Phase 3 VIVID-DME trial of EYLEA® (aflibercept) Injection for the treatment of diabetic macular edema (DME), EYLEA 2 milligrams (mg) dosed monthly (2Q4) and EYLEA 2 mg dosed every two months (after 5 initial monthly injections, 2Q8) showed a sustained improvement from baseline in best corrected visual acuity (BCVA) at week 100 (2 years), compared to laser photocoagulation. [More]
Researchers discover crucial process that regulates development of blood vessels

Researchers discover crucial process that regulates development of blood vessels

Biologists at The Scripps Research Institute (TSRI) have discovered a crucial process that regulates the development of blood vessels. [More]
CenterVue's next generation Macular Integrity Assessment receives FDA clearance

CenterVue's next generation Macular Integrity Assessment receives FDA clearance

CenterVue, Inc., a leader in the design and manufacture of highly automated medical devices for the diagnosis and management of ocular pathologies, today announced FDA 510(k) clearance has been granted for the company's next generation Macular Integrity Assessment (MAIA). [More]
Study shows high BP drugs may raise likelihood of age-related macular degeneration

Study shows high BP drugs may raise likelihood of age-related macular degeneration

There may be a connection between taking vasodilators and developing early-stage age-related macular degeneration (AMD), the leading cause of vision loss and blindness among Americans who are age 65 and older, according to a study published online in Ophthalmology, the journal of the American Academy of Ophthalmology. [More]
Study reveals 70% of patients with diabetic retinopathy will develop macular edema

Study reveals 70% of patients with diabetic retinopathy will develop macular edema

In Mexico, at least 14 million people have developed macular edema due to diabetes (DME), which like retinopathy affects central vision and can lead to blindness if not treated early . [More]
New drug approach for safer clean-up of deformed blood vessels in eye

New drug approach for safer clean-up of deformed blood vessels in eye

A new drug approach has been developed for safer clean-up of deformed blood vessels in the eye by a research team at the Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital in Toronto. [More]
Genetic biomarkers of ranibizumab response remain elusive in Koreans with AMD

Genetic biomarkers of ranibizumab response remain elusive in Koreans with AMD

Researchers have failed to find a significant genotypic effect on ranibizumab treatment response in Korean patients with neovascular age-related macular degeneration. [More]

Ranibizumab trial gets promising results for CNV

Patients with visual impairment due to myopic choroidal neovascularisation achieve better visual acuity after 3 months of individualised treatment with ranibizumab than with verteporfin photodynamic therapy, show the results of a phase III randomised controlled trial. [More]
Early gene therapy could improve choroideremia prognosis

Early gene therapy could improve choroideremia prognosis

Retinal gene therapy could prevent loss of vision in patients with choroideremia and other retinal diseases, show the results of a phase I/II study. [More]
Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Australian and New Zealand patients with diabetes-induced vision loss to get access to new treatment

Australian and New Zealand patients suffering from vision impairment due to a type of diabetes-induced eye disease will have access to a new treatment, following a license deal between Australian biopharmaceutical company Specialised Therapeutics Australia and Alimera Sciences. [More]